Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others), By Sample Type (Tissue Biopsy and Liquid Biopsy), By Panel Type (Multi-Gene Panel and Single-Gene Panel), By End-User (Research Organization, Hospitals & Clinics
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationLung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others), By Sample Type (Tissue Biopsy and Liquid Biopsy), By Panel Type (Multi-Gene Panel and Single-Gene Panel), By End-User (Research Organization, Hospitals & Clinics
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 1.80 Billion |
| CAGR (2024-2029) | 5.25% |
| Fastest Growing Segment | Polymerase Chain Reaction |
| Largest Market | North America |
| Market Size (2029) | USD 2.45 Billion |
Global Lung Cancer Genomic Testing Medicine Market w
Lung cancer continues to be a global health concern, with a high incidence rate. This has created a substantial demand for more precise diagnostic and treatment options.
Key Market Drivers
Rising Incidence of Lung Cancer is Driving the Global Lung Cancer Genomic Testing Medicine Market
Lung cancer is one of the most common and deadliest forms of cancer worldwide, accounting for a substantial number of cancer-related deaths each year. The alarming rise in the incidence of lung cancer has prompted a significant shift in the way this disease is diagnosed and treated. Genomic testing, which involves analyzing the genetic makeup of lung cancer cells, has emerged as a powerful tool in the fight against this devastating disease. As the incidence of lung cancer continues to grow, the global lung cancer genomic testing medicine market is witnessing unprecedented growth
Smoking remains the leading cause of lung cancer, and despite significant efforts to reduce tobacco use, millions of people worldwide continue to smoke. This addictive habit continues to be a primary driver of lung cancer cases.
Increased Healthcare Spending is Driving the Global Lung Cancer Genomic Testing Medicine Market
One of the primary drivers behind the growth of the global lung cancer genomic testing medicine market is the substantial increase in healthcare spending worldwide. Governments, insurance companies, and private healthcare providers are investing heavily in the development and implementation of genomic testing for lung cancer patients
The impact of increased healthcare spending on the global lung cancer genomic testing medicine market is significant. As more countries invest in research, technology, and healthcare infrastructure, the market is experiencing rapid growth. It is not only the developed nations that are driving this market but also emerging economies that are recognizing the importance of precision medicine in their healthcare systems. Moreover, collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions have intensified due to the heightened focus on lung cancer genomic testing. This collective effort is facilitating the development of innovative solutions and the commercialization of new products, leading to further market expansion.
Key Market Challenges
Limited Awareness and Accessibility
One of the foremost challenges in the lung cancer genomic testing market is the limited awareness among patients, healthcare providers, and even governments. Many people are unaware of the existence and importance of these tests, resulting in underutilization. Furthermore, access to genomic testing varies significantly across different regions, and not all patients have the opportunity to benefit from this advanced technology. Ensuring that patients and physicians are well-informed and expanding access to testing is crucial for market growth.
Cost Constraints
The cost of genomic testing can be a significant barrier for many patients and healthcare systems. High costs associated with test development, equipment, and analysis often translate to expensive tests, limiting their availability and affordability. To address this challenge, there is a need for ongoing research to reduce testing costs and for healthcare systems to consider reimbursing patients for these tests to make them more accessible.
Data Privacy and Security
Genomic testing generates a vast amount of sensitive patient data, including genetic information that has the potential for misuse if not adequately protected. Privacy concerns and data security challenges are a significant hurdle in the adoption of genomic testing. The industry needs to establish robust data protection protocols and regulatory frameworks to address these concerns and ensure patient trust.
Standardization and Regulation
The lung cancer genomic testing medicine market lacks standardized protocols for testing, reporting, and interpretation of results. This inconsistency can lead to discrepancies in the quality of testing and results, affecting patient care. Establishing comprehensive regulations and guidelines is essential to ensure the accuracy and reliability of genomic testing across the globe.
Evolving Genomic Landscape
The field of genomics is continually evolving, with new discoveries and technologies emerging at a rapid pace. This presents both an opportunity and a challenge for the lung cancer genomic testing market. Keeping up with the latest advancements in genomics and integrating them into clinical practice is vital, but it also requires ongoing investments in research, development, and training.
Resistance to Change
Changing traditional healthcare practices and introducing genomic testing into clinical workflows can be met with resistance from both healthcare providers and patients. There may be skepticism and reluctance to embrace new technologies and shift away from conventional treatment approaches. Effective educational and advocacy efforts are necessary to overcome this challenge.
Ethical Dilemmas
Genomic testing in lung cancer raises ethical questions regarding data use, informed consent, and potential discrimination based on genetic information. These ethical dilemmas must be addressed through transparent policies and guidelines to ensure that patients' rights and well-being are protected.
Key Market Trends
Technological Advancements
The global healthcare industry is experiencing a profound transformation, driven by technological advancements that are changing the way diseases are diagnosed, treated, and managed. In the realm of cancer care, one area where these innovations are making a significant impact is in the field of genomic testing for lung cancer. Lung cancer is a major global health concern, and as the second most common cancer, early detection and personalized treatment are essential for improving patient outcomes. The rise of genomic testing has opened new horizons in the battle against lung cancer, and it is propelling the global Lung Cancer Genomic Testing Medicine Market to new heights
Next-Generation Sequencing (NGS) technologies have revolutionized genomic testing, enabling the comprehensive analysis of a patient's DNA. This has led to a deeper understanding of the genetic mutations responsible for lung cancer, allowing for more precise and personalized treatment plans.
Segmental Insights
Technology Insights
Based
PCR is a rapid technique that can generate results in a matter of hours, allowing healthcare providers to make timely decisions about patient care. This speed is especially important in the fast-paced world of cancer treatment.
Sample type Insights
The Tissue Biopsy segment is projected to experience rapid growth during the forecast period. Tissue biopsy, which involves extracting a small sample of lung tissue for analysis, has emerged as the primary method for conducting genomic testing in lung cancer cases. Tissue biopsy provides a comprehensive view of the genetic mutations and alterations present in a patient's tumor. This comprehensive analysis enables oncologists to make more accurate and personalized treatment decisions. Tissue biopsy is known for its accuracy and reliability in identifying genomic alterations. It is considered the gold standard for detecting specific mutations and guiding treatment choices. Lung cancer is a highly heterogeneous disease, with genetic changes occurring at different sites within the tumor. Tissue biopsy allows for the assessment of this intra-tumor heterogeneity, providing a more accurate representation of the genetic landscape of the cancer. Genomic testing from tissue biopsy can identify predictive biomarkers, such as EGFR mutations or ALK rearrangements, which can guide the selection of targeted therapies. This approach leads to more successful treatment outcomes and fewer adverse effects.
Regional Insights
North America emerged as the dominant region in the global Lung Cancer Genomic Testing Medicine market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, has been at the forefront of lung cancer genomic testing medicine research and innovation. World-class research institutions, medical centers, and pharmaceutical companies in the region have invested heavily in the development of cutting-edge technologies and therapies. This has contributed to North America's leadership in the field. The region boasts a significant presence of advanced technology companies and genomic sequencing centers that offer state-of-the-art equipment and expertise in genomic testing. This accessibility to cutting-edge technology has allowed North American healthcare providers to offer comprehensive genomic testing services to lung cancer patients.
Recent Developments
- In February 2024, the Centers for Medicare & Medicaid Services (CMS) approved reimbursement for a genetic test designed by researchers at Washington University School of Medicine in St. Louis. This test, named GatewaySeq, detects cancer mutations present in solid tumors such as those found in the lung, colon, and pancreas. By pinpointing mutations that can be targeted with existing medications, GatewaySeq facilitates the advancement of precision medicine treatment approaches for patients with solid tumors.GatewaySeq represents the latest addition to Washington University's suite of genetic assessment tools to receive CMS approval. Other recent tests include ChromoSeq, a whole-genome sequencing test tailored for the initial diagnosis of blood cancers like acute myeloid leukemia and myelodysplastic syndrome, and MyeloSeq, utilized for monitoring the efficacy of ongoing treatment for blood and bone marrow cancers such as acute myeloid leukemia and myelodysplastic syndrome, among others.
Key Market Players
- QIAGEN NV
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- CENTOGENE N.V.
- BGI Genomics Co. Ltd.
- CeGaT GmbH
- Illumina Inc.
- F. Hoffmann-La Roche Ltd
| By Technology | By Sample Type | By Panel Type | By End-User | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy